Ketamine Assisted Psychotherapy

Ketamine assisted psychotherapy is a novel approach to treating various psychiatric conditions, including major depressive disorder, anxiety, and post-traumatic stress disorders. This therapy combines prescribed doses of ketamine, an analgesic anesthetic with dissociative properties, with psychotherapy to produce promising results. With its potential to rapidly alleviate symptoms of mental illnesses, ketamine assisted psychotherapy has gained significant attention in recent years. Researchers and clinicians, such as [[phil-wolfson|Phil Wolfson]], are working to further understand the therapeutic potential of ketamine and its applications in treating mental health disorders. As of 2022, the Food and Drug Administration (FDA) has approved the use of ketamine for treatment-resistant depression, marking a significant milestone in the development of this therapy. According to a study published in the Journal of Psychopharmacology, ketamine has shown a response rate of 50-60% in patients with treatment-resistant depression, making it a valuable treatment option for those who have not responded to traditional therapies.